Loading…
Optimization of bacteriophage therapy for difficult-to-treat musculoskeletal infections: a bench-to-bedside perspective
Given the increasing threat of antimicrobial resistance, scientists are urgently seeking adjunct antimicrobial strategies, such as phage therapy (PT). However, despite promising results for the treatment of musculoskeletal infections in our center, crucial knowledge gaps remain. Therefore, a prospec...
Saved in:
Published in: | Frontiers in cellular and infection microbiology 2024-09, Vol.14, p.1434397 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c350t-a5d52ffb2a0bd918f869039937a65074cac307d72b1fd68bf746343f6ae138a53 |
container_end_page | |
container_issue | |
container_start_page | 1434397 |
container_title | Frontiers in cellular and infection microbiology |
container_volume | 14 |
creator | Bessems, Laura Chen, Baixing Uyttebroek, Saartje Devolder, David Lood, Cédric Verwimp, Stefaan De Munter, Paul Debaveye, Yves Depypere, Melissa Spriet, Isabel Van Gerven, Laura Dupont, Lieven Wagemans, Jeroen van Noort, Vera Lavigne, Rob Metsemakers, Willem-Jan Onsea, Jolien |
description | Given the increasing threat of antimicrobial resistance, scientists are urgently seeking adjunct antimicrobial strategies, such as phage therapy (PT). However, despite promising results for the treatment of musculoskeletal infections in our center, crucial knowledge gaps remain. Therefore, a prospective observational study (PHAGEFORCE) and a multidisciplinary approach was set up to achieve and optimize standardized treatment guidelines. At our center, PT is strictly controlled and monitored by a multidisciplinary taskforce. Each phage treatment follows the same pathway to ensure standardization and data quality. Within the PHAGEFORCE framework, we established a testing platform to gain insight in the safety and efficacy of PT, biodistribution, phage kinetics and the molecular interaction between phages and bacteria. The draining fluid is collected to determine the phage titer and bacterial load. In addition, all bacterial isolates are fully characterized by genome sequencing to monitor the emergence of phage resistance. We hereby present a standardized bench-to-bedside protocol to gain more insight in the kinetics and dynamics of PT for musculoskeletal infections. |
doi_str_mv | 10.3389/fcimb.2024.1434397 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_9f03b4647a604f80a39d76426b68fb15</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_9f03b4647a604f80a39d76426b68fb15</doaj_id><sourcerecordid>3106462824</sourcerecordid><originalsourceid>FETCH-LOGICAL-c350t-a5d52ffb2a0bd918f869039937a65074cac307d72b1fd68bf746343f6ae138a53</originalsourceid><addsrcrecordid>eNpVksFu1DAQhiMEolXpC3BAPnLJ4tiOY3NBqKKlUqVe4GyNnfGuSxIH21tUnp6ku1TtXDwa__PNyP6r6n1DN5wr_cm7MNoNo0xsGsEF192r6pQx3tZMK_X6WX5Sned8R5foKFOav61OuGaa6q47rf7cziWM4S-UECcSPbHgCqYQ5x1skZQdJpgfiI-J9MH74PZDqUusS0IoZNznpRDzLxywwEDC5NGtpPyZALE4ud0qttjn0COZMeV5Fdzju-qNhyHj-fE8q35efvtx8b2-ub26vvh6Uzve0lJD27fMe8uA2l43yiupKdeadyBb2gkHjtOu75htfC-V9Z2Qy2N4CdhwBS0_q64P3D7CnZlTGCE9mAjBPBZi2hpIJbgBjfaUWyHFgqbCKwpc950UTFqpvG1W1pcDa97bEXuHU0kwvIC-vJnCzmzjvWkaQVtO6UL4eCSk-HuPuZgxZIfDABPGfTa8oVJIpphYpOwgdSnmnNA_zWmoWR1gHh1gVgeYowOWpg_PN3xq-f_f_B-X4LAm</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3106462824</pqid></control><display><type>article</type><title>Optimization of bacteriophage therapy for difficult-to-treat musculoskeletal infections: a bench-to-bedside perspective</title><source>PubMed (Medline)</source><creator>Bessems, Laura ; Chen, Baixing ; Uyttebroek, Saartje ; Devolder, David ; Lood, Cédric ; Verwimp, Stefaan ; De Munter, Paul ; Debaveye, Yves ; Depypere, Melissa ; Spriet, Isabel ; Van Gerven, Laura ; Dupont, Lieven ; Wagemans, Jeroen ; van Noort, Vera ; Lavigne, Rob ; Metsemakers, Willem-Jan ; Onsea, Jolien</creator><creatorcontrib>Bessems, Laura ; Chen, Baixing ; Uyttebroek, Saartje ; Devolder, David ; Lood, Cédric ; Verwimp, Stefaan ; De Munter, Paul ; Debaveye, Yves ; Depypere, Melissa ; Spriet, Isabel ; Van Gerven, Laura ; Dupont, Lieven ; Wagemans, Jeroen ; van Noort, Vera ; Lavigne, Rob ; Metsemakers, Willem-Jan ; Onsea, Jolien</creatorcontrib><description>Given the increasing threat of antimicrobial resistance, scientists are urgently seeking adjunct antimicrobial strategies, such as phage therapy (PT). However, despite promising results for the treatment of musculoskeletal infections in our center, crucial knowledge gaps remain. Therefore, a prospective observational study (PHAGEFORCE) and a multidisciplinary approach was set up to achieve and optimize standardized treatment guidelines. At our center, PT is strictly controlled and monitored by a multidisciplinary taskforce. Each phage treatment follows the same pathway to ensure standardization and data quality. Within the PHAGEFORCE framework, we established a testing platform to gain insight in the safety and efficacy of PT, biodistribution, phage kinetics and the molecular interaction between phages and bacteria. The draining fluid is collected to determine the phage titer and bacterial load. In addition, all bacterial isolates are fully characterized by genome sequencing to monitor the emergence of phage resistance. We hereby present a standardized bench-to-bedside protocol to gain more insight in the kinetics and dynamics of PT for musculoskeletal infections.</description><identifier>ISSN: 2235-2988</identifier><identifier>EISSN: 2235-2988</identifier><identifier>DOI: 10.3389/fcimb.2024.1434397</identifier><identifier>PMID: 39290977</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>Bacteria - virology ; Bacterial Infections - therapy ; bacteriophage therapy ; bacteriophages ; Bacteriophages - physiology ; bench-to-bedside ; Cellular and Infection Microbiology ; Humans ; Musculoskeletal Diseases - microbiology ; Musculoskeletal Diseases - therapy ; musculoskeletal infections ; Phage Therapy - methods ; Prospective Studies ; treatment optimization</subject><ispartof>Frontiers in cellular and infection microbiology, 2024-09, Vol.14, p.1434397</ispartof><rights>Copyright © 2024 Bessems, Chen, Uyttebroek, Devolder, Lood, Verwimp, De Munter, Debaveye, Depypere, Spriet, Van Gerven, Dupont, Wagemans, van Noort, Lavigne, Metsemakers and Onsea.</rights><rights>Copyright © 2024 Bessems, Chen, Uyttebroek, Devolder, Lood, Verwimp, De Munter, Debaveye, Depypere, Spriet, Van Gerven, Dupont, Wagemans, van Noort, Lavigne, Metsemakers and Onsea 2024 Bessems, Chen, Uyttebroek, Devolder, Lood, Verwimp, De Munter, Debaveye, Depypere, Spriet, Van Gerven, Dupont, Wagemans, van Noort, Lavigne, Metsemakers and Onsea</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c350t-a5d52ffb2a0bd918f869039937a65074cac307d72b1fd68bf746343f6ae138a53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11405300/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11405300/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39290977$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bessems, Laura</creatorcontrib><creatorcontrib>Chen, Baixing</creatorcontrib><creatorcontrib>Uyttebroek, Saartje</creatorcontrib><creatorcontrib>Devolder, David</creatorcontrib><creatorcontrib>Lood, Cédric</creatorcontrib><creatorcontrib>Verwimp, Stefaan</creatorcontrib><creatorcontrib>De Munter, Paul</creatorcontrib><creatorcontrib>Debaveye, Yves</creatorcontrib><creatorcontrib>Depypere, Melissa</creatorcontrib><creatorcontrib>Spriet, Isabel</creatorcontrib><creatorcontrib>Van Gerven, Laura</creatorcontrib><creatorcontrib>Dupont, Lieven</creatorcontrib><creatorcontrib>Wagemans, Jeroen</creatorcontrib><creatorcontrib>van Noort, Vera</creatorcontrib><creatorcontrib>Lavigne, Rob</creatorcontrib><creatorcontrib>Metsemakers, Willem-Jan</creatorcontrib><creatorcontrib>Onsea, Jolien</creatorcontrib><title>Optimization of bacteriophage therapy for difficult-to-treat musculoskeletal infections: a bench-to-bedside perspective</title><title>Frontiers in cellular and infection microbiology</title><addtitle>Front Cell Infect Microbiol</addtitle><description>Given the increasing threat of antimicrobial resistance, scientists are urgently seeking adjunct antimicrobial strategies, such as phage therapy (PT). However, despite promising results for the treatment of musculoskeletal infections in our center, crucial knowledge gaps remain. Therefore, a prospective observational study (PHAGEFORCE) and a multidisciplinary approach was set up to achieve and optimize standardized treatment guidelines. At our center, PT is strictly controlled and monitored by a multidisciplinary taskforce. Each phage treatment follows the same pathway to ensure standardization and data quality. Within the PHAGEFORCE framework, we established a testing platform to gain insight in the safety and efficacy of PT, biodistribution, phage kinetics and the molecular interaction between phages and bacteria. The draining fluid is collected to determine the phage titer and bacterial load. In addition, all bacterial isolates are fully characterized by genome sequencing to monitor the emergence of phage resistance. We hereby present a standardized bench-to-bedside protocol to gain more insight in the kinetics and dynamics of PT for musculoskeletal infections.</description><subject>Bacteria - virology</subject><subject>Bacterial Infections - therapy</subject><subject>bacteriophage therapy</subject><subject>bacteriophages</subject><subject>Bacteriophages - physiology</subject><subject>bench-to-bedside</subject><subject>Cellular and Infection Microbiology</subject><subject>Humans</subject><subject>Musculoskeletal Diseases - microbiology</subject><subject>Musculoskeletal Diseases - therapy</subject><subject>musculoskeletal infections</subject><subject>Phage Therapy - methods</subject><subject>Prospective Studies</subject><subject>treatment optimization</subject><issn>2235-2988</issn><issn>2235-2988</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVksFu1DAQhiMEolXpC3BAPnLJ4tiOY3NBqKKlUqVe4GyNnfGuSxIH21tUnp6ku1TtXDwa__PNyP6r6n1DN5wr_cm7MNoNo0xsGsEF192r6pQx3tZMK_X6WX5Sned8R5foKFOav61OuGaa6q47rf7cziWM4S-UECcSPbHgCqYQ5x1skZQdJpgfiI-J9MH74PZDqUusS0IoZNznpRDzLxywwEDC5NGtpPyZALE4ud0qttjn0COZMeV5Fdzju-qNhyHj-fE8q35efvtx8b2-ub26vvh6Uzve0lJD27fMe8uA2l43yiupKdeadyBb2gkHjtOu75htfC-V9Z2Qy2N4CdhwBS0_q64P3D7CnZlTGCE9mAjBPBZi2hpIJbgBjfaUWyHFgqbCKwpc950UTFqpvG1W1pcDa97bEXuHU0kwvIC-vJnCzmzjvWkaQVtO6UL4eCSk-HuPuZgxZIfDABPGfTa8oVJIpphYpOwgdSnmnNA_zWmoWR1gHh1gVgeYowOWpg_PN3xq-f_f_B-X4LAm</recordid><startdate>20240903</startdate><enddate>20240903</enddate><creator>Bessems, Laura</creator><creator>Chen, Baixing</creator><creator>Uyttebroek, Saartje</creator><creator>Devolder, David</creator><creator>Lood, Cédric</creator><creator>Verwimp, Stefaan</creator><creator>De Munter, Paul</creator><creator>Debaveye, Yves</creator><creator>Depypere, Melissa</creator><creator>Spriet, Isabel</creator><creator>Van Gerven, Laura</creator><creator>Dupont, Lieven</creator><creator>Wagemans, Jeroen</creator><creator>van Noort, Vera</creator><creator>Lavigne, Rob</creator><creator>Metsemakers, Willem-Jan</creator><creator>Onsea, Jolien</creator><general>Frontiers Media S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20240903</creationdate><title>Optimization of bacteriophage therapy for difficult-to-treat musculoskeletal infections: a bench-to-bedside perspective</title><author>Bessems, Laura ; Chen, Baixing ; Uyttebroek, Saartje ; Devolder, David ; Lood, Cédric ; Verwimp, Stefaan ; De Munter, Paul ; Debaveye, Yves ; Depypere, Melissa ; Spriet, Isabel ; Van Gerven, Laura ; Dupont, Lieven ; Wagemans, Jeroen ; van Noort, Vera ; Lavigne, Rob ; Metsemakers, Willem-Jan ; Onsea, Jolien</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c350t-a5d52ffb2a0bd918f869039937a65074cac307d72b1fd68bf746343f6ae138a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Bacteria - virology</topic><topic>Bacterial Infections - therapy</topic><topic>bacteriophage therapy</topic><topic>bacteriophages</topic><topic>Bacteriophages - physiology</topic><topic>bench-to-bedside</topic><topic>Cellular and Infection Microbiology</topic><topic>Humans</topic><topic>Musculoskeletal Diseases - microbiology</topic><topic>Musculoskeletal Diseases - therapy</topic><topic>musculoskeletal infections</topic><topic>Phage Therapy - methods</topic><topic>Prospective Studies</topic><topic>treatment optimization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bessems, Laura</creatorcontrib><creatorcontrib>Chen, Baixing</creatorcontrib><creatorcontrib>Uyttebroek, Saartje</creatorcontrib><creatorcontrib>Devolder, David</creatorcontrib><creatorcontrib>Lood, Cédric</creatorcontrib><creatorcontrib>Verwimp, Stefaan</creatorcontrib><creatorcontrib>De Munter, Paul</creatorcontrib><creatorcontrib>Debaveye, Yves</creatorcontrib><creatorcontrib>Depypere, Melissa</creatorcontrib><creatorcontrib>Spriet, Isabel</creatorcontrib><creatorcontrib>Van Gerven, Laura</creatorcontrib><creatorcontrib>Dupont, Lieven</creatorcontrib><creatorcontrib>Wagemans, Jeroen</creatorcontrib><creatorcontrib>van Noort, Vera</creatorcontrib><creatorcontrib>Lavigne, Rob</creatorcontrib><creatorcontrib>Metsemakers, Willem-Jan</creatorcontrib><creatorcontrib>Onsea, Jolien</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in cellular and infection microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bessems, Laura</au><au>Chen, Baixing</au><au>Uyttebroek, Saartje</au><au>Devolder, David</au><au>Lood, Cédric</au><au>Verwimp, Stefaan</au><au>De Munter, Paul</au><au>Debaveye, Yves</au><au>Depypere, Melissa</au><au>Spriet, Isabel</au><au>Van Gerven, Laura</au><au>Dupont, Lieven</au><au>Wagemans, Jeroen</au><au>van Noort, Vera</au><au>Lavigne, Rob</au><au>Metsemakers, Willem-Jan</au><au>Onsea, Jolien</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Optimization of bacteriophage therapy for difficult-to-treat musculoskeletal infections: a bench-to-bedside perspective</atitle><jtitle>Frontiers in cellular and infection microbiology</jtitle><addtitle>Front Cell Infect Microbiol</addtitle><date>2024-09-03</date><risdate>2024</risdate><volume>14</volume><spage>1434397</spage><pages>1434397-</pages><issn>2235-2988</issn><eissn>2235-2988</eissn><abstract>Given the increasing threat of antimicrobial resistance, scientists are urgently seeking adjunct antimicrobial strategies, such as phage therapy (PT). However, despite promising results for the treatment of musculoskeletal infections in our center, crucial knowledge gaps remain. Therefore, a prospective observational study (PHAGEFORCE) and a multidisciplinary approach was set up to achieve and optimize standardized treatment guidelines. At our center, PT is strictly controlled and monitored by a multidisciplinary taskforce. Each phage treatment follows the same pathway to ensure standardization and data quality. Within the PHAGEFORCE framework, we established a testing platform to gain insight in the safety and efficacy of PT, biodistribution, phage kinetics and the molecular interaction between phages and bacteria. The draining fluid is collected to determine the phage titer and bacterial load. In addition, all bacterial isolates are fully characterized by genome sequencing to monitor the emergence of phage resistance. We hereby present a standardized bench-to-bedside protocol to gain more insight in the kinetics and dynamics of PT for musculoskeletal infections.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>39290977</pmid><doi>10.3389/fcimb.2024.1434397</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2235-2988 |
ispartof | Frontiers in cellular and infection microbiology, 2024-09, Vol.14, p.1434397 |
issn | 2235-2988 2235-2988 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_9f03b4647a604f80a39d76426b68fb15 |
source | PubMed (Medline) |
subjects | Bacteria - virology Bacterial Infections - therapy bacteriophage therapy bacteriophages Bacteriophages - physiology bench-to-bedside Cellular and Infection Microbiology Humans Musculoskeletal Diseases - microbiology Musculoskeletal Diseases - therapy musculoskeletal infections Phage Therapy - methods Prospective Studies treatment optimization |
title | Optimization of bacteriophage therapy for difficult-to-treat musculoskeletal infections: a bench-to-bedside perspective |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T05%3A43%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Optimization%20of%20bacteriophage%20therapy%20for%20difficult-to-treat%20musculoskeletal%20infections:%20a%20bench-to-bedside%20perspective&rft.jtitle=Frontiers%20in%20cellular%20and%20infection%20microbiology&rft.au=Bessems,%20Laura&rft.date=2024-09-03&rft.volume=14&rft.spage=1434397&rft.pages=1434397-&rft.issn=2235-2988&rft.eissn=2235-2988&rft_id=info:doi/10.3389/fcimb.2024.1434397&rft_dat=%3Cproquest_doaj_%3E3106462824%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c350t-a5d52ffb2a0bd918f869039937a65074cac307d72b1fd68bf746343f6ae138a53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3106462824&rft_id=info:pmid/39290977&rfr_iscdi=true |